Every 10-Q that Revvity Inc (RVTY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RVTY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVTY filings page.
Revvity, Inc. reported second-quarter 2026 revenue of $729.7 million, up about 1% from $720.3 million a year earlier. Life Sciences revenue declined to $358.7 million while Diagnostics rose to $371.0 million, driven by Reproductive Health and favorable foreign exchange, offset by softer Software and Immunodiagnostics.
Gross margin improved to 57.1% from 54.5%, helped by $16.2 million of U.S. tariff refunds and product mix, but operating income from continuing operations was roughly flat at $89.3 million as $35.5 million of restructuring and other costs and higher SG&A offset the margin gains. Q2 net income was $51.8 million and diluted EPS was $0.47.
For the first six months of 2026, revenue reached $1.44 billion versus $1.39 billion, and operating cash flow from continuing operations increased to $317.8 million. Cash and cash equivalents were $1.02 billion against total debt of $3.22 billion. The company acquired Advanced Chemistry Development Inc. for $72.0 million plus up to $8.0 million in earn-out, continued share repurchases, paid a quarterly dividend of $0.07 per share, and agreed to divest its China Immunodiagnostics business, which represented about 6% of 2025 revenue.
Revvity, Inc. reported first-quarter fiscal 2026 revenue of $711.1 million, up 7% from $664.8 million a year earlier, with growth in both Life Sciences and Diagnostics and an extra fiscal week contributing. Life Sciences revenue rose to $361.8 million and Diagnostics to $349.3 million.
Gross margin narrowed from 56.5% to 54.5%, pressured by product mix, foreign exchange, higher tariffs and the extra week. Net income was $40.7 million, compared with $42.2 million, and diluted EPS was $0.36. Operating cash flow from continuing operations was $125.9 million, supporting ongoing share repurchases and dividends.
The company closed the $72 million acquisition of Advanced Chemistry Development Inc., recording $32.0 million of goodwill, and booked $10.7 million in restructuring and other costs tied to workforce reductions and facility consolidations affecting about 2% of employees. Revvity ended the quarter with $860.3 million in cash and cash equivalents and total debt of about $3.23 billion, while continuing to return capital through a $0.07 per share quarterly dividend and $79.0 million of stock buybacks under its $1.0 billion repurchase program.
Revvity, Inc. (RVTY) reported Q3 results with total revenue of $698.9 million, up 2% year over year. Diluted EPS was $0.40 as net income declined to $46.7 million amid higher interest and other expenses. Gross margin fell 266 bps to 53.6% and operating margin also compressed, driven by increased tariffs, unfavorable foreign exchange, and product mix.
By segment, Diagnostics rose 3% to $356.1 million, led by Reproductive Health, while Life Sciences inched up 1% to $342.8 million on stronger Software. Year‑to‑date cash from operations was $407.0 million. The company repurchased 6.75 million shares for $647.9 million year to date, ending the quarter with 114.0 million shares outstanding, and the Board authorized a new $1.0 billion repurchase program on October 23, 2025. The quarterly dividend remained $0.07 per share.
Revvity (RVTY) 10-Q – Q2 FY25 highlights
Total revenue rose 4% YoY to $720.3 m, with Life Sciences +5% and Diagnostics +3%. 1H revenue reached $1.39 bn (+3%). Gross margin slipped 123 bp to 54.5% as tariffs and mix offset price increases. SG&A efficiencies trimmed opex, lifting operating income 6% to $90.8 m and widening operating margin 20 bp to 12.6%.
Profitability
- Income from continuing ops fell 24% to $55.2 m; net income dipped 3% to $53.9 m due to lower discontinued-ops losses.
- Diluted EPS held at $0.46 (net) as a 5% share count reduction offset lower earnings.
Cash & Balance Sheet
- Operating cash flow from continuing ops declined 19% to $268.4 m; FCF after capex ≈ $233 m.
- Cash fell to $991.8 m (-15%) after $447.5 m of buybacks and $16.7 m of dividends.
- Long-term debt increased to $3.21 bn; net cash/(debt) now ≈ -$2.22 bn.
Capital returns
- Repurchased 4.43 m shares YTD for $443 m; $414.5 m remains on the $1 bn program.
- Quarterly dividend maintained at $0.07.
Other items: Intangible amortization $85.3 m; FX translation pushed OCI positive by $159 m; no goodwill impairments. Management warns FY25 gross profit could be cut ~$20 m by tariffs despite mitigation efforts.
Takeaway: Top-line momentum is steady and cost control improving operating margin, but core earnings, cash generation and gross margin are under pressure. Heavy buybacks temper EPS erosion while leverage inches higher.